the inefficient transport of oxygen by misshapen red blood cells. The disease, prevalent among people of color, occurs in 1 out of every 365 Black Americans and has historically suffered from underfunded research and inadequate medical attention, compounding the challenges faced by patients.
The newly approved gene therapies, Casgevy and Lyfgenia, involve modifying bone marrow cells responsible for red blood cell production. Through the use of innovative technologies, these therapies aim to replace unhealthy red blood cells with healthy ones, preventing the triggering of pain crises.
While gene therapy holds the promise of transforming lives, it necessitates vigilant post-procedure monitoring. Patients typically remain in close proximity to the hospital for testing, ensuring the effectiveness of the treatment and addressing any potential complications.
Despite the transformative potential, gene therapy is not without its challenges. The chemotherapy phase, while instrumental, brings its own set of side effects, including hair loss and weakness. Additionally, the impact on fertility and the need for careful monitoring post-procedure underscore the seriousness of the treatment.
RELATED: Everything you Need to Know About the New Treatment for Sickle Cell
While gene therapy offers a glimmer of hope for sickle cell patients, the cost remains a significant barrier. Casgevy, priced at $2.2 million, and Lyfgenia, priced at $3.1 million, are expensive treatments that may limit accessibility. The impact on insurance coverage and additional expenses, such as housing during monitoring periods, will influence the reach of gene therapy. Determining the ideal candidates for treatment is also a critical aspect that remains under consideration.
Dr. Stuart Orkin of Boston Children’s Hospital envisions leveraging the lessons learned from sickle cell gene therapy to develop more accessible and less expensive treatments. Researchers are exploring alternatives, including less toxic drugs and in-body genetic tinkering, with the goal of broadening the scope of treatment options. As the public becomes more aware of sickle cell disease through gene therapy advancements, there is hope for increased support, funding, and understanding for those affected by this often-overlooked condition.
If you are considering gene therapy, remember to approach the treatment with realistic expectations. While the therapy holds immense promise in preventing future damage, it cannot reverse the problems already caused by the disease. Early detection and treatment are still key for managing sickle cell disease.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
